BIOCON Stock Overview
Engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 2/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
Biocon Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹323.10 |
| 52 Week High | ₹395.80 |
| 52 Week Low | ₹231.25 |
| Beta | 0.46 |
| 11 Month Change | -0.83% |
| 3 Month Change | -8.11% |
| 1 Year Change | 37.69% |
| 33 Year Change | -10.87% |
| 5 Year Change | 13.87% |
| Change since IPO | 700.99% |
Recent News & Updates
Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results
Nov 02
Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E
Nov 01Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?
Oct 14Recent updates
Here's What Analysts Are Forecasting For Biocon Limited (NSE:BIOCON) After Its Second-Quarter Results
Nov 02Why Investors Shouldn't Be Surprised By Biocon Limited's (NSE:BIOCON) Low P/E
Nov 01Do Biocon's (NSE:BIOCON) Earnings Warrant Your Attention?
Oct 14These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Sep 20Biocon Limited's (NSE:BIOCON) Earnings Haven't Escaped The Attention Of Investors
Jun 29Is Biocon (NSE:BIOCON) A Risky Investment?
Jun 11Biocon (NSE:BIOCON) Is Reducing Its Dividend To ₹0.50
Jun 11Biocon's (NSE:BIOCON) Promising Earnings May Rest On Soft Foundations
May 24Biocon's (NSE:BIOCON) Dividend Is Being Reduced To ₹0.50
May 23Is Now The Time To Put Biocon (NSE:BIOCON) On Your Watchlist?
Mar 20Biocon Limited Just Beat EPS By 240%: Here's What Analysts Think Will Happen Next
Feb 12Biocon Limited's (NSE:BIOCON) Intrinsic Value Is Potentially 18% Below Its Share Price
Jan 23Shareholders Should Be Pleased With Biocon Limited's (NSE:BIOCON) Price
Jan 03These 4 Measures Indicate That Biocon (NSE:BIOCON) Is Using Debt Extensively
Nov 13Estimating The Intrinsic Value Of Biocon Limited (NSE:BIOCON)
Aug 03Biocon (NSE:BIOCON) Will Pay A Larger Dividend Than Last Year At ₹1.50
Jul 03Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 02Biocon's (NSE:BIOCON) Dividend Will Be Increased To ₹1.50
May 26Estimating The Fair Value Of Biocon Limited (NSE:BIOCON)
Mar 28Here's Why Biocon (NSE:BIOCON) Can Manage Its Debt Responsibly
Feb 26Biocon Limited (NSE:BIOCON) Shares Could Be 24% Above Their Intrinsic Value Estimate
Dec 17Is There An Opportunity With Biocon Limited's (NSE:BIOCON) 46% Undervaluation?
Sep 05Is Biocon (NSE:BIOCON) Using Too Much Debt?
Jul 13Biocon Limited (NSE:BIOCON) Shares Could Be 20% Below Their Intrinsic Value Estimate
May 26Shareholder Returns
| BIOCON | IN Biotechs | IN Market | |
|---|---|---|---|
| 7D | -3.8% | -0.5% | 0.3% |
| 1Y | 37.7% | 42.7% | 27.3% |
Return vs Industry: BIOCON underperformed the Indian Biotechs industry which returned 42.7% over the past year.
Return vs Market: BIOCON exceeded the Indian Market which returned 27.3% over the past year.
Price Volatility
| BIOCON volatility | |
|---|---|
| BIOCON Average Weekly Movement | 5.0% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: BIOCON has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: BIOCON's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 16,315 | Siddharth Mittal | www.biocon.com |
Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab.
Biocon Limited Fundamentals Summary
| BIOCON fundamental statistics | |
|---|---|
| Market cap | ₹391.42b |
| Earnings (TTM) | ₹14.39b |
| Revenue (TTM) | ₹148.94b |
26.9x
P/E Ratio2.6x
P/S RatioIs BIOCON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOCON income statement (TTM) | |
|---|---|
| Revenue | ₹148.94b |
| Cost of Revenue | ₹56.11b |
| Gross Profit | ₹92.83b |
| Other Expenses | ₹78.44b |
| Earnings | ₹14.39b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.03 |
| Gross Margin | 62.33% |
| Net Profit Margin | 9.66% |
| Debt/Equity Ratio | 60.4% |
How did BIOCON perform over the long term?
See historical performance and comparison